Table 1.
Cohort | UCSD* | TU* | LAOH* | p-value |
---|---|---|---|---|
# of patients | 114 | 120 | 224 | |
Mean Age | 41.3±14.5 | 37.5 ± 13.5 | 43.2 ± 15.5 | .003 |
Race | <.0001 | |||
White | 56(49.1%) | 84(70.0%) | 103(45.8%) | |
Black | 11(9.7%) | 25(20.8%) | 14(6.2%) | |
Hispanic | 31(27.2%) | 1(0.8%) | 78(34.7%) | |
Other | 16(14.0%) | 10(8.3%) | 30(13.3%) | |
Hemophilia | .44 | |||
A | 90(79.0%) | 89(74.2%) | 183(81.3%) | |
B | 24(21.0%) | 31(25.8%) | 41(18.2%) | |
Unknown | 0 | 0 | 1(0.4%) | |
Inhibitor | <.0001 | |||
Positive | 4(3.5%) | 17(14.2%) | 8(3.6%) | |
Negative | 70(61.4%) | 103(85.8%) | 207(92.0%) | |
Not Tested | 40(35.1%) | 0 | 10(4.4%) | |
Severity | <.0001 | |||
Severe | 50(43.9%) | 69(57.5%) | 134(59.6%) | |
Moderate | 17(14.9%) | 30(25.0%) | 17(7.8%) | |
Mild | 46(40.4%) | 21(17.5%) | 66(29.3%) | |
Unknown | 1(0.9%) | 0 | 8(3.6%) | |
HIV Status | <.0001 | |||
Positive | 27(23.7%) | 20(16.7%) | 58(25.8%) | |
Negative | 62(54.4%) | 93(77.5%) | 167(74.2%) | |
Not Tested | 25(21.9%) | 7(5.8%) | 0 | |
Hepatitis | <.0001 | |||
Positive | 62(54.4%) | 71(59.2%) | 168(74.7%) | |
Negative | 38(33.3%) | 45(37.5%) | 54(24.0%) | |
Not Tested | 14(12.3%) | 4(3.3%) | 3(1.3%) | |
Mean BMI | 27.9 ± 6.6 | 27.1 ± 5.3 | 26.9 ± 5.7 | .31 |
Smoking | <.0001 | |||
Ever | 20(16.8%) | 40(33.3%) | 54(34.2%) | |
Never | 99(83.2%) | 80(66.7%) | 91(57.6%) | |
Unknown | - | - | 13(8.2%) | |
Diabetes | 0.17 | |||
Yes | 7(6.1%) | 5(4.2%) | 24(10.7%) | |
No | 107 (93.9%) | 115(95.8%) | 200(88.9%) | |
Unknown | 0 | 0 | 1 (0.4%) | |
Median Creatinine | 0.84(0.22) | 0.90(0.30) | 0.80(0.30) | .0002 |
Meane GFR | 106.3 ± 21.7 | 101.9 ± 25.2 | 102.1 ± 24.6 | .28 |
University of California San Diego = UCSD; Tulane University=TU; Los Angeles Orthopedic Hospital (LAOH); BMI = Body Mass Index; eGFR=estimated Glomerular Filtration Rate